Global Human Rabies Immunoglobulin (IM) Competitive Landscape Professional Research Report 2024

Global Human Rabies Immunoglobulin (IM) Competitive Landscape Professional Research Report 2024

Research Summary

Human Rabies Immunoglobulin (HRIG) is a specialized immunoglobulin preparation used in the post-exposure prophylaxis of rabies. When an individual is potentially exposed to the rabies virus through bites or scratches from an infected animal, HRIG is administered as a part of the rabies vaccination protocol. HRIG contains a high concentration of rabies antibodies derived from the plasma of individuals previously vaccinated against rabies. The administration of HRIG provides immediate passive immunity by supplying the patient with pre-formed antibodies, offering rapid protection against the virus while the rabies vaccine induces an active immune response. HRIG is typically administered at the site of the wound or exposure and, if possible, infiltrated into and around the wound. It is a crucial component of the rabies post-exposure prophylaxis regimen and is used in conjunction with rabies vaccinations to prevent the onset of rabies in individuals who may have been exposed to the virus.

According to DIResearch's in-depth investigation and research, the global Human Rabies Immunoglobulin (IM) market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Human Rabies Immunoglobulin (IM) include CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Bharat Serum, Shanghai RAAS, VINS etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Human Rabies Immunoglobulin (IM). Focus on analysing the market share, product portfolio, prices, sales volume, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Human Rabies Immunoglobulin (IM) market. The report data covers historical data from 2019 to 2023, based year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Human Rabies Immunoglobulin (IM) market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Human Rabies Immunoglobulin (IM) industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.    

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Human Rabies Immunoglobulin (IM) Include:

CSL Behring

Grifols

Sanofi

Sichuan Yuanda Shuyang

CNBG

Kamada

CBPO

Shuanglin Bio

Weiguang Bio

Bharat Serum

Shanghai RAAS

VINS

Human Rabies Immunoglobulin (IM) Product Segment Include:

ERIG

HRIG

Human Rabies Immunoglobulin (IM) Product Application Include:

Category II Exposure

Category III Exposure

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Human Rabies Immunoglobulin (IM) Industry PESTEL Analysis

Chapter 3: Global Human Rabies Immunoglobulin (IM) Industry Porter’s Five Forces Analysis

Chapter 4: Global Human Rabies Immunoglobulin (IM) Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis

Chapter 5: Global Human Rabies Immunoglobulin (IM) Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Human Rabies Immunoglobulin (IM) Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources